Last reviewed · How we verify

SOMATROPINE* : Norditropine® simplexx®

Assistance Publique - Hôpitaux de Paris · Phase 2 active Small molecule

SOMATROPINE* : Norditropine® simplexx® is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently in Phase 2 development. Also known as: SOMATROPINE.

At a glance

Generic nameSOMATROPINE* : Norditropine® simplexx®
Also known asSOMATROPINE
SponsorAssistance Publique - Hôpitaux de Paris
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about SOMATROPINE* : Norditropine® simplexx®

What is SOMATROPINE* : Norditropine® simplexx®?

SOMATROPINE* : Norditropine® simplexx® is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris.

Who makes SOMATROPINE* : Norditropine® simplexx®?

SOMATROPINE* : Norditropine® simplexx® is developed by Assistance Publique - Hôpitaux de Paris (see full Assistance Publique - Hôpitaux de Paris pipeline at /company/assistance-publique-h-pitaux-de-paris).

Is SOMATROPINE* : Norditropine® simplexx® also known as anything else?

SOMATROPINE* : Norditropine® simplexx® is also known as SOMATROPINE.

What development phase is SOMATROPINE* : Norditropine® simplexx® in?

SOMATROPINE* : Norditropine® simplexx® is in Phase 2.

Related